Anfarm Hellas S.A. - Main Component
| Active Substance | Strength | Form |
|---|---|---|
| L-carnitine | 1g, 2g/10ml Vial | Oral.Sol |
| LacosamideUnder Development | 10mg/ml | Sol.Inf |
| LacosamideUnder Development | 10mg/ml | Oral Solution |
| Lansoprazole | 30mg | GR.Cap |
| Levofloxacin | 5mg/ml (100ml Bottle) | Sol.Inf |
| Linezolid | 2mg/ml (300ml Plastic Bag) | Sol.Inf |
| Lisinopril | 20mg, 40mg | Tab |
| Loratadine | 10mg | Tab |
| Losartan Potassium | 100mg | F.C.Tab |
| Active Substance | Strength | Form |
|---|---|---|
| L-carnitine | 1g, 2g/10ml Vial | Oral.Sol |
| LacosamideUnder Development | 10mg/ml | Sol.Inf |
| LacosamideUnder Development | 10mg/ml | Oral Solution |
| Lansoprazole | 30mg | GR.Cap |
| Levofloxacin | 5mg/ml (100ml Bottle) | Sol.Inf |
| Linezolid | 2mg/ml (300ml Plastic Bag) | Sol.Inf |
| Lisinopril | 20mg, 40mg | Tab |
| Loratadine | 10mg | Tab |
| Losartan Potassium | 100mg | F.C.Tab |
| Active Substance | Strength | Form | Market Availability |
|---|---|---|---|
| L-carnitine | 1g, 2g/10ml Vial | Oral.Sol | International |
| LacosamideUnder Development | 10mg/ml | Sol.Inf | Q1 2021 |
| LacosamideUnder Development | 10mg/ml | Oral Solution | Q2 2022 |
| Lansoprazole | 30mg | GR.Cap | Selected Markets |
| Levofloxacin | 5mg/ml (100ml Bottle) | Sol.Inf | International |
| Linezolid | 2mg/ml (300ml Plastic Bag) | Sol.Inf | International |
| Lisinopril | 20mg, 40mg | Tab | Selected Markets |
| Loratadine | 10mg | Tab | Selected Markets |
| Losartan Potassium | 100mg | F.C.Tab | Selected Markets |
